OTCQB
RGRX

Regenerx Biopharm In

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Regenerx Biopharm In Stock Price

Vitals

Today's Low:
$0.013
Today's High:
$0.0178
Open Price:
$0.016
52W Low:
$0.01
52W High:
$3
Prev. Close:
$0.02
Volume:
83686

Company Statistics

Market Cap.:
$2.40 million
Book Value:
-0.026
Revenue TTM:
$76760
Operating Margin TTM:
-1775.75%
Gross Profit TTM:
$70123
Profit Margin:
0%
Return on Assets TTM:
-148.5%
Return on Equity TTM:
0%

Company Profile

Regenerx Biopharm In had its IPO on 1986-12-23 under the ticker symbol RGRX.

The company operates in the Healthcare sector and Biotechnology industry. Regenerx Biopharm In has a staff strength of 2 employees.

Stock update

Shares of Regenerx Biopharm In opened at $0.02 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.01 - $0.02, and closed at $0.02.

This is a -23% slip from the previous day's closing price.

A total volume of 83,686 shares were traded at the close of the day’s session.

In the last one week, shares of Regenerx Biopharm In have slipped by -23%.

Regenerx Biopharm In's Key Ratios

Regenerx Biopharm In has a market cap of $2.40 million, indicating a price to book ratio of 0 and a price to sales ratio of 261.8127.

In the last 12-months Regenerx Biopharm In’s revenue was $76760 with a gross profit of $70123 and an EBITDA of $-1293125. The EBITDA ratio measures Regenerx Biopharm In's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Regenerx Biopharm In’s operating margin was -1775.75% while its return on assets stood at -148.5% with a return of equity of 0%.

In Q1, Regenerx Biopharm In’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Regenerx Biopharm In’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Regenerx Biopharm In’s profitability.

Regenerx Biopharm In stock is trading at a EV to sales ratio of 298.4489 and a EV to EBITDA ratio of -15.686. Its price to sales ratio in the trailing 12-months stood at 261.8127.

Regenerx Biopharm In stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$186810.00
Total Liabilities
$1.80 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Regenerx Biopharm In ended 2024 with $186810.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $186810.00 while shareholder equity stood at $-3744335.00.

Regenerx Biopharm In ended 2024 with $0 in deferred long-term liabilities, $1.80 million in other current liabilities, in common stock, $-112602368.00 in retained earnings and $0 in goodwill. Its cash balance stood at $101557.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $262015.00.

Regenerx Biopharm In’s total current assets stands at $123257.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $38693.00 and inventory worth $0.

In 2024, Regenerx Biopharm In's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Regenerx Biopharm In paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.02
52-Week High
$3
52-Week Low
$0.01
Analyst Target Price
$

Regenerx Biopharm In stock is currently trading at $0.02 per share. It touched a 52-week high of $3 and a 52-week low of $3. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.09 and 200-day moving average was $0.1 The short ratio stood at 0.15 indicating a short percent outstanding of 0%.

Around 4413.7% of the company’s stock are held by insiders while 0.7% are held by institutions.

Frequently Asked Questions About Regenerx Biopharm In

The stock symbol (also called stock or share ticker) of Regenerx Biopharm In is RGRX

The IPO of Regenerx Biopharm In took place on 1986-12-23

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$1.09
0.07
+6.86%
$61.2
-0.06
-0.1%
$90.17
-5.02
-5.27%
$5040.95
-137.95
-2.66%
$29.21
0.53
+1.85%
$13.83
0.06
+0.44%
$105.65
-9
-7.85%
$7.8
0.13
+1.69%
$140.8
-14.65
-9.42%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee’s Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Address

15245 Shady Grove Road, Rockville, MD, United States, 20850